Earnings season is off and running, and that means many golden opportunities to check in with the most important stocks in the health care industry.
With new U.S. health care policies going into effect, pressures from European austerity pressuring sales in the Old World, and large but often uncertain opportunities presented in developing markets, there's a lot of noise to distract investors from company-specific dynamics at work.
In the following video, health care bureau chief Brenton Flynn tries to cut through the noise and offers some of his key takeaways from last week's Amgen (NASDAQ: AMGN ) earnings report.
One of the most exciting stocks in the biotech space is Celgene. With its broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.